**BERLIN / ISTANBUL**
Shares in German pharmaceutical and chemical company Bayer fell 8% on Monday as of 1320 GMT after being sentenced late Friday to pay $2.1 billion to a US plaintiff over the controversial weed killer glyphosate.
A jury in a US court in the state of Georgia ordered the German company to pay $2.1 billion, including $65 million in compensatory damages and $2 billion in punitive damages, to a plaintiff who alleged that Bayer's Roundup weed killer caused harm, including cancer.
The jury also found that Bayer failed to adequately disclose the potential risks of using Roundup and was liable for failing to warn plaintiffs of the dangers of the drug.
In a statement, Bayer denied the allegations against glyphosate, saying it disagreed with the jury's verdict because it contradicted the overwhelming weight of scientific evidence and the consensus and worldwide scientific assessments of regulatory agencies. The company will appeal the final verdict, as it has in all other cases.
Damages in cases that have reached final verdicts have generally been reduced by 90% compared to the original jury verdicts, it added.
In 2018, Bayer was ordered to pay billions of dollars in fines and damages in lawsuits brought by those who claimed that the pesticide Roundup, developed by the company after its $63 billion acquisition of US agricultural company Monsanto, was a key cancer trigger.
While Bayer denied the allegation, in 2015 the International Agency for Research on Cancer classified glyphosate as a carcinogen.
Bayer announced in 2020 that it had settled lawsuits filed against it in the US and would pay $10.9 billion to plaintiffs.
Despite the settlement, the company faces more than 60,000 lawsuits related to Roundup. The German firm has set aside $5.9 billion in legal provisions for these lawsuits.
[Anadolu Agency website contains only a portion of the news stories offered to subscribers in the AA News Broadcasting System (HAS), and in summarized form. **Please contact us for subscription options.**](https://www.aa.com.tr/en/p/subscription/1001)